March 9, 2020 / 3:18 AM / 25 days ago

BRIEF-Biocon Says FDA Accepts Biologics License Application For Mylan, Co's Proposed Biosimilar Bevacizumab For Review

March 9 (Reuters) - Biocon Ltd:

* BIOCON LTD - U.S. FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) FOR MYLAN AND BIOCON’’S PROPOSED BIOSIMILAR BEVACIZUMAB FOR REVIEW

* BIOCON LTD SAYS FDA GOAL DATE SET UNDER BIOSIMILAR USER FEE ACT IS DEC 27, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below